Protara Therapeutics Announces Dosing Of First Patient In Phase 2 STARBORN-1 Trial Of TARA-002 In Pediatric Patients With Lymphatic Malformations
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics has announced the dosing of the first patient in its Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations. This marks a significant step in the company's clinical development program.
October 23, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protara Therapeutics has started dosing in its Phase 2 trial of TARA-002. This could potentially lead to positive outcomes for the company if the trial results are successful.
The initiation of dosing in a Phase 2 trial is a significant milestone in a company's clinical development program. If the trial results are positive, this could potentially lead to regulatory approval and commercialization of the drug, which would be a significant revenue driver for the company. Therefore, this news is highly relevant and important for investors in Protara Therapeutics.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100